Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- Multitarget Stool DNA Versus Fecal Immunochemical Testing: A National Assessment of Follow-Up Colonoscopy by Race and Ethnicity (National Comprehensive Cancer Network)
- Physician Fee Schedule 2027: What physicians need to know now (Medical Economics)
- Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer (Business Wire)
- What Happens to Independent Medicine When Private Equity Shows Up With a Checkbook (MedCity News)
- AGA launches AI-powered virtual assistant for gastroenterology and hepatology care (News Medical)
- AMSURG Acquires 5 Endoscopy Centers in North Carolina (ASC News)
- Hawaii mandates free follow-up colonoscopies, wipes $91M in medical debt (Becker’s Healthcare)
- Endo Tools Therapeutics Secures $23 million in Series C Financing to Advance The endomina® technology and Commercialization of New endomina EZFuse System (Endo Tools Therapeutics)
